Ab­b­Vie un­veils lat­est round of im­munol­o­gy schol­ar­ships for pa­tients with chron­ic dis­ease

An­oth­er 45 stu­dents with chron­ic, im­mune-me­di­at­ed dis­eases are go­ing to col­lege with a lit­tle help from Ab­b­Vie.

Ab­b­Vie an­nounced the re­cip­i­ents of this year’s Im­munol­o­gy Schol­ar­ship on Thurs­day, a group of stu­dents who have “ex­em­pli­fied de­ter­mi­na­tion to over­come chal­lenges,” Ab­b­Vie’s US pres­i­dent of im­munol­o­gy Patrick Hor­ber said in a news re­lease.

While best known for its port­fo­lio of im­munol­o­gy drugs such as Rin­voq, Skyrizi or block­buster Hu­mi­ra — which faces an im­pend­ing patent cliff — Ab­b­Vie launched its im­munol­o­gy schol­ar­ship pro­gram back in 2016 to prove its com­mit­ment to help­ing pa­tients out­side of fill­ing pre­scrip­tions.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.